ZoetisNYSE: ZTS

Zoetis Inc. (NYSE:ZTS ) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation.

Zoetis, a top company in animal health, has experienced remarkable growth with a 17.55% compound annual growth rate (CAGR) since going public, surpassing the S&P 500. The rise in pet ownership and spending worldwide helps the company maintain steady revenues, even during economic challenges. Additionally, Zoetis has a strong competitive advantage due to its wide range of products, solid patent protections, and ongoing investment in research and development.

PARSIPPANY, N.J.--(BUSINESS WIRE)--ZOETIS HAS NAMED JAMIE BRANNAN AS THE FIRST CHIEF COMMERCIAL OFFICER.

I maintain a 'Buy' recommendation for Zoetis, setting a target price of $210 per share for the next year, thanks to impressive product results and smart sales of non-core assets. The company's osteoarthritis medications, LIBRELA and SOLENSIA, saw a 97% increase in operational revenue, with LIBRELA expected to reach $1 billion in sales. Zoetis anticipates a 10-11% growth in operational revenue and a 13.5-14.5% rise in adjusted net income for FY24, even with some challenges from China.

ZTS stock rises after the third-quarter results exceeded expectations for both earnings and revenue, thanks to strong product sales. The management has also improved the outlook for 2024.

Zoetis Inc (NYSE:ZTS, ETR:ZOE) had a strong third quarter for fiscal year 2024, with both revenue and earnings beating Wall Street predictions. For the quarter ending on September 30, 2024, the animal health company reported revenues of $2.39 billion, which is an 11% rise from $2.15 billion in the same period last year, and it exceeded analysts' expectations of $2.29 billion.

On Monday, Zoetis increased its yearly profit and revenue predictions due to high demand for its animal medicines and vaccines.

Zoetis (ZTS) reported quarterly earnings of $1.58 per share, which is higher than the Zacks Consensus Estimate of $1.46 per share. This is an increase compared to earnings of $1.36 per share from the same period last year.

Zoetis Inc. (NYSE:ZTS) will hold its Q3 2024 Earnings Conference Call on November 4, 2024, at 8:30 AM ET. The call will feature company representatives including Steve Frank, the Vice President of Investor Relations, and Kristin Peck, the CEO. Various financial analysts from different firms will also participate in the call.